---
title: Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy
  for Adults With Relapsed/Refractory B-Cell ALL
date: '2024-10-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39418622/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241018202919&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Similar to ZUMA-3, high rates of MRD-negative CR were observed
  after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel
  resulted in improved ...'
disable_comments: true
---
CONCLUSION: Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved ...